Feline Upper Respiratory Infection (FURI) and Zoonotic Potential: Clinical Management and One Health Considerations
Introduction
Feline upper respiratory infection (FURI) represents a complex, multifactorial disease syndrome of domestic cats, with etiologic agents spanning viral, bacterial, and occasionally parasitic or fungal pathogens [1, 2, 3]. The clinical spectrum ranges from mild serous nasal discharge and conjunctivitis to severe ulcerative keratitis, pneumonia, and systemic disease [4, 3, 34]. Beyond individual patient morbidity, FURI pathogens carry variable zoonotic potential, a dimension that remains underappreciated in routine clinical practice [5, 6, 7]. The question "is cat respiratory infection contagious to humans" is increasingly relevant given the emergence of highly pathogenic avian influenza A(H5N1) in domestic cats and documented occupational exposures in veterinary personnel [5, 6, 8]. This article provides an exhaustive review of the major viral and bacterial agents of FURI, their zoonotic implications, diagnostic approaches, therapeutic management, and prevention strategies within a One Health framework.
Etiologic Agents of FURI
FURI is most frequently caused by felid alphaherpesvirus 1 (FeAHV-1, commonly FHV-1) and feline calicivirus (FCV), with secondary bacterial invaders such as Bordetella bronchiseptica, Chlamydia felis, and Mycoplasma species contributing to disease severity and chronicity [1, 2, 3, 9]. Co-infections are the rule rather than the exception; a Bulgarian single-center study reported high rates of co-infection between FHV-1, FCV, Mycoplasma spp., and C. felis in cats presenting with respiratory signs during the post-pandemic period [1]. Similarly, a Brazilian study during the COVID-19 pandemic documented frequent co-detection of multiple URTD pathogens, underscoring the syndemic nature of FURI [2].
Viral Pathogens
Feline herpesvirus type 1 (FHV-1): This enveloped DNA virus, a member of the Alphaherpesvirinae subfamily, establishes lifelong latency in trigeminal ganglia after primary infection [3, 9]. Reactivation occurs during stress, immunosuppression, or corticosteroid administration, leading to recurrent clinical signs [10]. FHV-1 preferentially infects mucosal epithelium of the upper respiratory tract and conjunctiva, causing intranuclear inclusion bodies and syncytia formation [3]. The virus alters the diversity of the upper respiratory tract microbiota, potentially facilitating secondary bacterial overgrowth [10]. Molecular detection methods, including conventional PCR, droplet digital PCR (ddPCR), and immunochromatographic test strips with fluorescent microspheres, offer rapid and sensitive diagnosis [11, 12]. The ddPCR assay demonstrated superior quantitation and sensitivity compared to qPCR for FHV-1 detection in clinical samples [12].
Feline calicivirus (FCV): FCV is a non-enveloped, single-stranded positive-sense RNA virus belonging to the Caliciviridae family [13]. Its high mutation rate drives extensive antigenic diversity, complicating vaccine efficacy [14, 15, 13]. FCV typically causes oral ulceration, salivation, and upper respiratory signs, but virulent systemic strains (VS-FCV) can produce severe systemic disease with footpad edema, cutaneous edema, and fatal pneumonia [4, 16, 17]. Recent studies have documented FCV localization in central nervous system cells of cats with neurological lesions, expanding the recognized tropism of this pathogen [18]. The leader of the capsid protein must be palmitoylated and form oligomers through disulfide bonds for efficient viral replication, highlighting a post-translational requirement for infectivity [19]. Reverse genetics systems have been constructed for FCV field strains, enabling proteomic and transcriptomic analyses of host-virus interactions [20, 14, 21]. A novel genogroup of FCV has been discovered through molecular evolution in group-housed cats in China, suggesting ongoing viral diversification [33]. Engineered VP1 mRNA vaccines have demonstrated induction of immunity and complete protection against FCV challenge in cats [22].
Bacterial Pathogens
Bordetella bronchiseptica: This Gram-negative coccobacillus is a primary and secondary pathogen in feline respiratory disease, frequently isolated from cats housed in high-density environments such as shelters and multicat households [2, 23]. B. bronchiseptica produces adhesins and toxins that damage ciliated respiratory epithelium, promoting colonization and persistence [2]. It is a recognized zoonotic agent, especially in immunocompromised human contacts, and is capable of causing respiratory disease in dogs, pigs, and laboratory animals [2].
Chlamydia felis: An obligate intracellular Gram-negative bacterium, C. felis is a significant cause of conjunctivitis in cats, often with mild upper respiratory signs [1]. Ocular manifestations include chemosis, hyperemia, and serous to mucopurulent discharge [1, 24]. Zoonotic transmission of C. felis to humans is rare but documented, typically presenting as conjunctivitis in immunocompromised individuals [1].
Mycoplasma species: Hemotropic and non-hemotropic mycoplasmas, including Mycoplasma felis and Mycoplasma gatae, are frequently isolated from the upper respiratory tract of cats with FURI [25, 1]. A large epidemiological study in China demonstrated phylogenetic divergence and differential pathogenicity among feline respiratory mycoplasma strains, with some isolates causing severe pneumonia in experimental infections [25]. Mycoplasmas lack cell walls, making them inherently resistant to beta-lactam antibiotics, and their small genome limits metabolic capacity, requiring host-derived nutrients [25].
Other bacterial and mycobacterial agents: Mycobacterium orygis, an emerging zoonotic pathogen, has been reported as a cause of fatal pulmonary tuberculosis in a cat in India, underscoring the potential for interspecies transmission of atypical mycobacteria [7]. Streptococcus canis, Pasteurella multocida, and Escherichia coli may also contribute to secondary bacterial pneumonia in FURI patients [26, 3].
Is Cat Respiratory Infection Contagious to Humans? Zoonotic Risk Assessment
The zoonotic potential of FURI pathogens varies by agent, host immunocompetence, and route of exposure. The question "is cat respiratory infection contagious to humans" must be answered with a pathogen-specific analysis.
Bordetella bronchiseptica is the bacterial agent with the best-documented zoonotic transmission from cats to humans [2]. Immunocompromised individuals, including those with HIV/AIDS, organ transplants, or on chemotherapy, are at highest risk for developing a pertussis-like respiratory illness after contact with infected cats [2]. Direct transmission occurs via aerosolized respiratory secretions or fomites. Veterinarians and shelter workers should exercise standard precautions when managing cats with acute respiratory signs.
Chlamydia felis has been linked to human conjunctivitis through direct contact with ocular secretions from infected cats [1]. Cases are sporadic and typically occur in household contacts. The organism is susceptible to tetracyclines and macrolides in both feline and human patients.
Mycoplasma species: While Mycoplasma felis has been isolated from humans with respiratory disease, definitive zoonotic transmission is rare [25]. The phylogenetic divergence of feline-derived mycoplasmas suggests a species barrier, but immunocompromised patients may be susceptible.
Viral zoonotic risks: FHV-1 is not considered a human pathogen. FCV does not infect humans. However, the emergence of highly pathogenic avian influenza A(H5N1) in domestic cats represents a major One Health concern. In 2024-2025, H5N1 infection was confirmed in cats in Germany and Poland, with a veterinary professional in Los Angeles County developing serologic evidence of infection after exposure to an infected domestic cat [5, 6, 8]. Ex-vivo infection of cat lung explant cultures with SARS-CoV-2 Delta and Omicron variants demonstrated that feline respiratory tissues support viral replication, and an in vivo feline model revealed neutrophil dynamics similar to human COVID-19 [27, 32]. Although SARS-CoV-2 transmission from cats to humans remains poorly documented, the potential for reverse zoonosis and subsequent spillback exists [27, 32].
Mycobacterium orygis is a member of the Mycobacterium tuberculosis complex and is capable of causing tuberculosis in humans [7]. The fatal pulmonary infection in a cat from India highlights the need for diagnostic vigilance when cats present with chronic respiratory signs unresponsive to conventional therapy [7].
In summary, while most FURI agents pose minimal risk to healthy humans, B. bronchiseptica and C. felis are bona fide zoonotic pathogens. The emergence of H5N1 and other influenza A viruses in cats necessitates enhanced surveillance and biosecurity in veterinary settings. The question "is cat respiratory infection contagious to humans" should prompt a risk-based discussion with clients, especially those who are immunocompromised or live with young children.
Clinical Signs and Pathophysiology
Clinical manifestations of FURI reflect the tropism of the infecting agent and the host immune response. Serous to mucopurulent nasal discharge, sneezing, conjunctivitis, and ocular discharge are hallmarks [24, 3]. FHV-1 typically causes severe conjunctivitis, keratitis, and corneal ulceration, often with dendritic ulcers identified on fluorescein staining [24, 3]. FCV infection is characterized by oral ulceration on the tongue, hard palate, and lips, often accompanied by salivation and anorexia [4, 16, 13]. VS-FCV strains can produce systemic signs including pyrexia, cutaneous edema, and fatal pneumonia [4].
Bacterial infections may present with purulent nasal discharge, cough, and, in severe cases, bronchopneumonia [25, 26, 2]. Otitis media and middle ear disease are frequently concurrent with upper respiratory disease in cats, as evidenced by computed tomographic studies that demonstrate united airway disease involving the middle ear, upper, and lower airways [34].
Ophthalmic manifestations are particularly common in kittens and include chemosis, conjunctival hyperemia, and symblepharon formation in chronic FHV-1 infections [24]. Acute-phase proteins such as serum amyloid A and haptoglobin are elevated in cats with respiratory diseases and may serve as biomarkers of inflammation and disease severity [28].
Parasitic causes of feline respiratory disease, while less common, should be considered in endemic regions; lungworm infections (e.g., Aelurostrongylus abstrusus) have been reported in cats from southern Poland [29].
Diagnostic Approaches
Accurate etiologic diagnosis of FURI is essential for targeted therapy, infection control, and zoonotic risk assessment. Sample types include conjunctival, nasal, and pharyngeal swabs, as well as bronchoalveolar lavage fluid in pneumonia cases.
Molecular diagnostics: PCR-based assays are the gold standard for detecting FHV-1, FCV, C. felis, Mycoplasma spp., and B. bronchiseptica [1, 12, 23, 9]. Droplet digital PCR for FHV-1 offers absolute quantitation without standard curves, improving precision for viral load monitoring [12]. Multiplex PCR panels are commercially available and can simultaneously detect multiple pathogens [23]. An automated portable LAMP-based centrifugal microfluidic system has been developed for point-of-care detection of multiple FURI pathogens, providing rapid results in shelter and field settings [23]. Chemical sensors and biosensors are emerging as tools for individualized point-of-care diagnostics in companion animals [35].
Serology: Antibody detection for FHV-1 and FCV is useful for population-level seroprevalence studies and vaccine response assessment but has limited value in individual diagnosis due to widespread vaccination [15, 9].
Culture and sensitivity: Bacterial culture is indicated when bacterial pneumonia or multidrug resistance is suspected. B. bronchiseptica and C. felis require specialized media (Regan-Lowe, McCoy cells) [2]. Antibiograms guide antimicrobial selection, and systematic reviews suggest that shorter antibiotic durations (7 days) may be as effective as longer courses (14 days) for bacterial pneumonia in dogs and cats, reducing selection pressure for resistance [26].
Imaging: Thoracic radiography is recommended in cats with suspected pneumonia or lower airway involvement. Computed tomography provides detailed assessment of concurrent middle ear and airway disease [34].
The following Mermaid diagram outlines a clinical decision algorithm for FURI diagnosis and management.
flowchart TD
A[Cat presents with respiratory signs: sneezing, nasal discharge, conjunctivitis, oral ulcers], > B{Severity assessment}
B, >|Mild to moderate| C[Obtain conjunctival/nasal swab]
C, > D[Perform multiplex PCR for FHV-1, FCV, B. bronchiseptica, C. felis, Mycoplasma spp.]
D, > E{Pathogen identified?}
E, >|Yes| F[Targeted treatment based on pathogen]
E, >|No| G[Supportive care, consider bacterial culture if purulent discharge]
B, >|Severe or systemic signs| H[Hospitalize: IV fluids, oxygen, thoracic radiographs]
H, > I[Perform PCR panel and bacterial culture]
I, > J[Administer empiric broad-spectrum antibiotics if bacterial suspected]
J, > K[Monitor response, de-escalate based on results]
F, > L[Assess zoonotic risk if B. bronchiseptica or C. felis detected]
L, > M[Advise immunocompromised owners on precautions]
G, > N[Re-evaluate in 7 days; if no improvement, repeat diagnostics]
Therapeutic Management
Treatment of FURI is pathogen-specific and supportive. Antiviral therapy for FHV-1 includes systemic or topical famciclovir, which reduces viral shedding and clinical signs [24]. Cidofovir ophthalmic solution is used for severe FHV-1 keratitis [24]. Supportive care includes saline nebulization, gentle nasal flushes, and nutritional support with highly palatable foods or appetite stimulants.
Bacterial infections require antimicrobial therapy. B. bronchiseptica is often susceptible to tetracyclines (doxycycline), fluoroquinolones, and potentiated sulfonamides, but resistance is increasing [26, 2]. C. felis responds well to doxycycline or azithromycin [1]. Mycoplasma spp. are intrinsically resistant to beta-lactams; doxycycline or fluoroquinolones are first-line choices [25, 1]. Antibiograms should be performed for recurrent or refractory cases.
The duration of antibiotic therapy for bacterial pneumonia in dogs and cats has been systematically reviewed; current evidence suggests that shorter courses (7 days) are non-inferior to longer courses (14 days) for clinical cure, promoting antimicrobial stewardship [26]. In cases of severe feline coronavirus infection (feline infectious peritonitis), mesenchymal stem/stromal cell therapy has shown promise in improving immune recovery, although this is not a standard FURI treatment [30].
Prevention and Control Strategies
Vaccination remains the cornerstone of FURI prevention. Modified-live or inactivated vaccines against FHV-1 and FCV are widely used and reduce disease severity [22, 13]. The development of engineered VP1 mRNA vaccines for FCV represents a novel platform that induces robust humoral and cellular immunity without the risk of reversion to virulence [22]. Vaccination against B. bronchiseptica is available for cats in high-risk environments (shelters, boarding facilities) and should be considered on a case-by-case basis [2].
Biosecurity measures in multicat environments include isolation of affected cats, disinfection with agents effective against non-enveloped viruses (e.g., accelerated hydrogen peroxide, bleach for FCV), and personal protective equipment for personnel [5, 13]. Monitoring for H5N1 in cats with respiratory signs and a history of exposure to wild birds or infected poultry is critical for early detection and prevention of occupational exposure [5, 6].
One Health Implications
FURI is no longer viewed as a purely feline-specific syndrome. The zoonotic potential of B. bronchiseptica and C. felis, together with the emergence of influenza A(H5N1) in cats and the detection of Mycobacterium orygis in a feline patient, place feline respiratory disease firmly within a One Health framework [5, 6, 7, 8, 2]. Veterinary professionals are at the frontline of surveillance, and cases of unusual or severe respiratory disease in cats should be reported to public health authorities when zoonotic agents are suspected [5, 6]. The presence of gammaherpesvirus in cats with respiratory disease warrants further investigation into its potential role in immunosuppression and co-infection dynamics [31]. Deep learning models for predicting viral host-range transitions may eventually aid in assessing the pandemic potential of emerging feline pathogens [see related article: /knowledge/bioinformatics/deep-learning-for-predicting-viral-host-range-transitions-and-zoonotic-potential].
Conclusion
Feline upper respiratory infection is a multifactorial syndrome with viral, bacterial, and occasional mycobacterial or parasitic causes. The question "is cat respiratory infection contagious to humans" has a nuanced answer: most agents are species-specific, but B. bronchiseptica, C. felis, and highly pathogenic avian influenza A(H5N1) pose genuine zoonotic risks. Accurate diagnosis using modern molecular tools, targeted antimicrobial therapy with judicious duration, and comprehensive preventive strategies including vaccination and biosecurity are essential for clinical management and public health protection. A One Health approach that integrates veterinary, medical, and environmental surveillance is required to mitigate zoonotic risks from feline respiratory pathogens.
References
[1] Sirakov I, Krastanova M, Rusenova N, et al. Prevalence, clinical signs, diagnosis and treatment of post-pandemic SARS-CoV-2 infection in cats in 2023: co-infection with FHV, FCV, Mycoplasma spp. and Chlamydia felis-a single-center study in Bulgaria. Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42076746/
[2] de Oliveira Santana W, Maciel JG, Flores RS, et al. Epidemiology and co-infection of URTD pathogens in domestic cats during COVID-19. Braz J Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41405820/
[3] Slaviero M, de Almeida BA, de Castro LT, et al. Feline herpesvirus and calicivirus: occurrence and pathology in cats with respiratory disease. Top Companion Anim Med. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41015115/
[4] Magliocca M, Mandrioli L, Battilani M, et al. Description of a virulent systemic feline calicivirus infection in a kitten with footpads oedema and fatal pneumonia. Pathogens. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41305419/
[5] Dressler A, Wagner-Wiening C, Tegtmeyer B, et al. Highly pathogenic avian influenza A(H5N1) in poultry and domestic cats and occupational exposure among veterinary and other first responders, Germany, February 2026. Euro Surveill. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42141860/
[6] Vaughan A, Joyce A, Traub E, et al. Serologic evidence of highly pathogenic avian influenza A(H5N1) virus infection in a veterinary professional exposed to an infected domestic cat - Los Angeles County, California, December 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42096344/
[7] Mitra N, Jadhao A, Dhende AV, et al. First report of fatal feline pulmonary tuberculosis caused by the emerging zoonotic pathogen Mycobacterium orygis in a cat from India. Vet Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41712109/
[8] Adaszek Ł, Domańska-Blicharz K, Jańczak D, et al. Cats infected with H5N1 avian influenza - a new infectious disease in Poland. Pol J Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41416603/
[9] Acar G, Bilge-Dagalp S, Fedai T, et al. Molecular epidemiology of feline calicivirus (FCV) and felid alphaherpesvirus 1 (FeAHV-1) in cats with clinical signs and clinically healthy cats. Comp Immunol Microbiol Infect Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40644818/
[10] Li L, Feng W, Bi L, et al. Feline herpesvirus type 1 infection alters the diversity of upper respiratory tract microbiota in cats. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40919029/
[11] Shao P, Lian Y, Liu X, et al. Rapid and sensitive detection of feline herpesvirus-1 using fluorescent microspheres as labels for immunochromatographic test strips. Vet Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41779066/
[12] Zhou Y, Wu D, Tang M, et al. Development and validation of a droplet digital PCR assay for detection of feline herpesvirus type-1. Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41295745/
[13] Di Profio F, Carnevale M, Marsilio F, et al. Feline calicivirus infection: current understanding and implications for control strategies. Animals (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40723472/
[14] Kwan E, Legione AR, Hartley CA, et al. Transcriptomic analysis of Crandell-Rees feline kidney cell infections with field and vaccine feline calicivirus strains. Virus Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41435987/
[15] Xue X, Zhao G, Fang C, et al. Characterization and immunogenic evaluation of feline calicivirus epidemic strains. J Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40765225/
[16] Karakaya-Bilen E, Akgül G, Yılmaz-Koc O. Suspected feline calicivirus infection triggering ulcerative oral and skin lesions in cats following routine ovariohysterectomy: a postoperative risk assessment. Vet Med Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40728089/
[18] Phongroop K, Lacharoje S, Wardhani SW, et al. Feline calicivirus localization in central nervous system cells of cats with neurological lesions. Vet Anim Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42181094/
[19] Peñaflor-Téllez Y, Gómez de la Madrid J, Monge-Celestino EI, et al. The leader of the capsid protein from Feline calicivirus must be palmitoylated and form oligomers through disulfide bonds for efficient viral replication. J Virol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40827917/
[20] Xu C, Zhao J, Liu H, et al. Construction of reverse genetics system for feline calicivirus FCV-BJ616 and proteomic analysis. Microbiologyopen. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41603492/
[21] Zhang R, Zhu H, Zhao G, et al. Transcriptome analysis of Crandell Rees Feline Kidney (CRFK) cells infected with Feline calicivirus strain 023 (FCV 023). Virology. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41110383/
[22] Zhang MD, Xie ZF, Li XH, et al. Engineered VP1 mRNA vaccine induces immunity and complete protection against feline calicivirus in cats. Transbound Emerg Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41658352/
[23] Bi W, Wen F, Cai S, et al. An automated portable LAMP-based centrifugal microfluidic system for nucleic acid detection of multiple pathogens in feline upper respiratory disease. Mikrochim Acta. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40993306/
[24] Charnock L, Vernau K, Burkitt-Creedon J, et al. Clinical management of ophthalmic manifestations of upper respiratory tract infections in kittens. Vet Clin North Am Small Anim Pract. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41484008/
[25] Ye Z, Wang C, Yan Q, et al. Epidemiology, phylogenetic divergence, and differential pathogenicity of feline respiratory mycoplasma in China. Transbound Emerg Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42253332/
[26] Emdin F, Emdin A, Ong SWX, et al. Shorter versus longer durations of antibiotic treatment for pneumonia in dogs and cats: a systematic review and meta-analysis. J Am Vet Med Assoc. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41547037/
[27] Panwar A, Raut AA, Bhatia S, et al. Comparative temporal transcriptome analyses of SARS-CoV-2 delta and omicron variants ex-vivo infection in cat lung explant culture. Front Cell Infect Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41200555/
[28] Gareis H, Schulz B. Evaluation of amyloid A and haptoglobin in the serum of cats with respiratory diseases. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42109870/
[29] Dzimira S, Kandefer-Gola M, Ciaputa R, et al. Cases of lungworm in cats from southern Poland in the autopsy and cytological material. Pathogens. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40732678/
[30] Wanakumjorn P, Kimura K, Castillo D, et al. Mesenchymal stem/stromal cell therapy improves immune recovery in a feline model of severe coronavirus infection. Stem Cells Transl Med. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40659357/
[31] Doğan F, Acar G, Fedai̇ T, et al. Investigation of the presence of gammaherpesvirus infections in cats with and without upper respiratory tract disease. Comp Immunol Microbiol Infect Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42035571/